SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Smal
5 hours ago
- #Tiragolumab
- #Small Cell Lung Cancer
- #Phase 3 Trial
- SKYSCRAPER-02C is a phase 3 study in China comparing tiragolumab + atezolizumab + carboplatin/etoposide (CE) versus atezolizumab + CE in untreated extensive-stage small cell lung cancer.
- The experimental arm showed a median progression-free survival (PFS) of 5.6 months vs. 5.4 months in controls (HR=0.65), and median overall survival (OS) of 18.7 vs. 13.5 months (HR=0.89), with no new safety signals.
- Biomarker analysis indicated benefit in patients with specific molecular subtypes (NMF3/SCLC-I-NE, NMF4/SCLC-I-nNE) and high T-effector and tumor-associated macrophage immune signatures.
- The study suggests numerical improvements in PFS and OS with tiragolumab combination in Chinese ES-SCLC patients, and identifies immune-inflamed signatures to guide future TIGIT-based strategies.